Ali McBride, PharmD, MS, BCPS, clinical coordinator of hematology/oncology at the University of Arizona Cancer Center, discusses areas where pharmacists still have questions about biosimilars and their implementation.
Transcript
Other areas which are kind of coming and delving into more discussion in regards to education and other resources is, of course, what will happen for implementation in the near future, and also pharmacovigilance: How are we tracking this? Are we doing a good job of tracking this? Who's running that ship as well?
The last thing, which is still emerging and has not been had guidance yet, is interchangeability.* We're expecting the draft guidance document, which is actually brought back, to be released here shortly, hopefully in May, and that will provide us with more information about how we can actually switch these biosimilars before we can switch these with therapeutic interchange at many hospitals, clinic sites across the board.
But what happens when it goes to a specialty pharmacy outside of your network? Will they be able to switch a pegfilgrastim for self-injection? Will they be able to actually self-inject a short-acting growth factor without contacting the doctor?
We have seen a lot of state laws being passed, and there’s going to be state regulation with state boards of pharmacy, but also the federal law and state law may have to have further discussions as well.
So I think those areas, and hopefully they’re not too much, provide some opportunities for further discussion, and also opportunities for patients who are trying to get these drugs at a lower cost and also improve access as well.
*As of the date of filming. To read about the FDA’s finalized guidance on interchangeability, click here.
PBM Evolution Toward Value-Based Care Shifts to Transparent Pharmacy Pricing
March 30th 2025Josh Canavan, PharmD, RazorMetrics, and Chris O'Dell, Turquoise Health, predict pharmacy benefit managers (PBMs) will evolve toward value-based care, mirroring the broader shift toward open-cost structures.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Empowering Vulnerable Populations: The Path to Equitable Biologic Therapy Access
December 22nd 2024Elie Bahou, PharmD, senior vice president and system chief pharmacy officer at Providence, discusses strategies to improve equitable access to biologic therapies, including tiered formularies, income-based cost sharing, patient assistance programs, and fostering payer partnerships.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Can Global Policies to Boost Biosimilar Adoption Work in the US?
November 17th 2024On this special episode of Not So Different honoring Global Biosimilars Week, Craig Burton, executive director of the Biosimilars Council, explores how global policies—from incentives to health equity strategies—could boost biosimilar adoption in the US.
Q&A With Dr Chelsee Jensen: Navigating FDA Approvals, Challenges in the Biosimilar Landscape
January 14th 2024Chelsee Jensen, PharmD, BCPS, senior pharmacy specialist and pharmaceutical formulary manager at Mayo Clinic, reacts to the biggest FDA approvals of 2023 and how she sees the adalimumab, natalizumab, and tocilizumab spaces playing out.